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Abstract 
Background: Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their 
impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs with 
respect to incident type 2 diabetes in individuals with impaired glucose tolerance (IGT), and CV outcomes in those 
with IGT or type 2 diabetes.
Methods: We used PubMed and SCOPUS to identify randomized controlled trials reporting the incidence of type 2 
diabetes and/or CV outcomes that had compared AGIs with placebo in populations with IGT or type 2 diabetes, with 
or without established CV disease. Eligible studies were required to have ≥ 500 participants and/or ≥ 100 endpoints of 
interest. Meta-analyses of available trial data were performed using random effects models to calculate hazard ratios 
(HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes and CV outcomes.
Results: Of ten trials identified, three met our inclusion criteria for incident type 2 diabetes and four were eligible for 
CV outcomes. The overall HR (95% CI) comparing AGI with placebo for incident type 2 diabetes was 0.77 (0.67–0.88), 
p < 0.0001, and for CV outcomes was 0.98 (0.89–1.10), p = 0.85. There was little to no heterogeneity between studies, 
with  I2 values of 0.03% (p = 0.43) and 0% (p = 0.79) for the two outcomes respectively.
Conclusions: Allocation of people with IGT to an AGI significantly reduced their risk of incident type 2 diabetes by 
23%, whereas in those with IGT or type 2 diabetes the impact on CV outcomes was neutral.
Keywords: Impaired glucose tolerance, Type 2 diabetes, Cardiovascular disease, Alpha glucosidase inhibitor, Meta-
analysis
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Background
Alpha-glucosidase inhibitors (AGIs) such as acarbose, 
miglitol and voglibose are oral drugs used in the man-
agement of diabetes, primarily to reduce post-prandial 
glucose concentrations. Their use in individuals with 
impaired glucose tolerance (IGT) has been shown to 
delay progression to diabetes, but their effects on cardio-
vascular (CV) outcomes remain uncertain [1]. A previous 
systematic review evaluated the effects of acarbose on 
various outcomes, including CV, but it did not include a 
meta-analysis of randomized controlled trials [2].
STOP-NIDDM was a placebo-controlled randomized 
trial conducted in centres across Canada, Germany, 
Austria, Norway, Denmark, Sweden, Finland, Israel, and 
Spain that randomly allocated participants with IGT to 
100  mg acarbose or placebo three times daily [3]. The 
trial showed a 25% reduction in the incidence of type 2 
diabetes with acarbose, compared with placebo (hazard 
ratio (HR) 0.75, 95% confidence interval (CI) 0.63–0.90, 
p = 0.001) over a mean follow-up of 3.3  years. A pre-
specified secondary analysis, also showed that there 
was a 49% reduction in cardiovascular outcomes over 
the same time period (HR 0.51 [0.28–0.95], p = 0.03) 
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suggesting that acarbose might confer cardio protection, 
although this finding was based on only 47 CV events 
in total. Similarly, a meta-analysis of seven studies con-
ducted between 1987 and 1999 reported a reduction in 
myocardial infarction (MI) in individuals assigned acar-
bose compared with placebo, but was based on only 28 
events [4]. When a composite CV outcome (MI, stroke, 
CV death, angina or coronary revascularization) was 
examined, a 35% reduction in events was demonstrated 
based on 167 events in total [4].
The recently completed Acarbose Cardiovascular Eval-
uation (ACE) trial [5] was a randomized, double-blind, 
placebo-controlled, phase 4 study conducted in China 
that recruited patients with coronary heart disease and 
IGT. Participants were randomly allocated to acarbose 
(50  mg three times daily) or placebo, given in addition 
to fully-optimized CV secondary prevention therapy. 
The ACE trial showed that acarbose delayed progres-
sion to type 2 diabetes by 18% (odds ratio 0.82 (95% CI 
0.71–0.94, p = 0.005) but was neutral with respect to 
major adverse cardiovascular events (HR 0.98, 0.86–1.11, 
p = 0.73).
The aim of this analysis was to identify the overall 
impact of AGIs with respect to incident type 2 diabetes 
specifically in individuals with IGT, and on combined CV 
outcomes in those with IGT or type 2 diabetes.
Methods
Data sources and searches
We conducted a meta-analysis of randomized placebo-
controlled trials of AGIs in populations with IGT or 
type 2 diabetes, with or without established CV dis-
ease. Guidelines published by the Cochrane Collabora-
tion for the conduct of a meta-analysis and the PRISMA 
checklist [6] for reporting were followed to ensure best 
practice. This meta-analysis was registered with PROS-
PERO, an international prospective register of systematic 
reviews. PROSPERO registration provides transparency 
in the review process and helps counter publication bias 
by providing a permanent record of prospectively regis-
tered reviews, whether they are eventually published or 
not. Our PROSPERO submission included publication of 
key information relating to the design and conduct of the 
meta-analysis [7].
Two reviewers (RLC, CABS) independently screened 
titles/abstracts and full texts for eligibility, assessed risk 
of bias, and collected data from each eligible study. Any 
reviewer disagreements were resolved by discussion. Eth-
ics approval and patient consent were not required for 
these analyses.
We used PubMed and SCOPUS to conduct literature 
searches to identify relevant studies, with no language 
restrictions for trials from inception up to the 28th of 
February 2018. An initial search of published systematic 
reviews/meta-analyses concerning AGIs was performed 
to identify commonly used terms relating to AGIs. Pre-
defined search terms (plus spelling variations) included 
“alphaglucosidase inhibitor”, “acarbose”, “voglibose”, 
“miglitol”, “cardiovascular outcomes”, “type 2 diabetes”, 
“impaired glucose tolerance”, “postprandial hypergly-
caemia”, “dysglycemia” and “randomized controlled tri-
als”. For these analyses, only published articles were 
considered.
Study selection
The search results were filtered to include only those 
randomized controlled trials comparing an AGI with 
placebo on progression to type 2 diabetes and/or CV out-
comes in individuals with IGT or type 2 diabetes, with 
or without a history of CV disease. To avoid the inclu-
sion of short-term small-scale trials with little or no out-
come data, we specified in advance that those selected 
should have a ≥ 500 human participants and/or ≥ 100 
pre-defined cardiovascular/diabetes events, with at least 
1 year of follow up. Trials reporting CV outcomes were 
required to include as a minimum all three components 
of a major adverse cardiovascular event (MACE-3) com-
posite outcome defined as CV death, non-fatal MI or 
non-fatal stroke. Trials reporting diabetes outcomes 
were required to specify type 2 diabetes diagnosed by 
two successive glucose values (fasting plasma glucose 
[FPG] ≥ 7.0 mmol/l or 2-h post challenge plasma glucose 
[2hrPG] ≥ 11.1 mmol/l).
Data extraction and quality assessment
Sources of reporting bias, e.g. publication bias, language 
bias, citation bias, were examined using funnel plots.
Data synthesis and analysis
Study-level data for all eligible trials identified were 
extracted from their corresponding published papers. 
We performed a random effects meta-analysis, with each 
study weighted according to the inverse variance method. 
HRs and 95% CIs were calculated for both incident dia-
betes and CV outcomes. Possible heterogeneity between 
studies was examined using Cochrane’s Q-test and the 
 I2 inconsistency index used to quantify the percentage 
of total variation across all the studies. A Q test P-value 
of < 0.05 indicates significant heterogeneity.  I2 heteroge-
neity thresholds are defined as low (≤ 25%), moderate 
(26–49%) or high (≥ 50%) [8]. The same statistical meth-
odologies were applied separately to incident diabetes 
and to CV outcomes. All analyses were performed using 
SAS version 9.4 and/or R version 3.4.0 [9].
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Results
Incident diabetes
Our literature search identified 157 articles, of which 
there were ten trials that met the criteria for possible 
inclusion in the incident diabetes meta-analysis (Fig. 1), 
but only three remained eligible after detailed review. 
These were the Study to Prevent Non-Insulin-Depend-
ent Diabetes Mellitus (STOP-NIDDM), [3] the voglibose 
Ph-3 Study, [10] and the ACE trial [5] (Table 1). Partici-
pants in these trials were at high risk of developing type 2 
diabetes, but people experiencing a CV event in the pre-
screening period (3  months for ACE, 6  months for the 
other 2 studies) were excluded. All three trials reported 
statistically significant relative risk reductions for inci-
dent diabetes in the treatment group, compared with the 
placebo group, of 25%, 40% and 18% for STOP-NIDDM, 
voglibose Ph-3 and ACE respectively. This equated to an 
overall 23% reduction for AGIs (HR 0.77, 95% CI 0.67–
0.88, p < 0.0001), with an  I2 value of 0.03% (p = 0.43) sug-
gesting minimal heterogeneity between studies (Fig.  2), 
and the funnel plot (Additional file 1: Figure S1) indicat-
ing that publication bias is unlikely.  
Cardiovascular outcomes
Of the 187 articles identified in the literature search, 
there were ten trials that met the criteria for possible 
inclusion in the CV outcomes meta-analysis (Fig.  1), 
but only four of these remained eligible after detailed 
review. These were the UK Prospective Diabetes Study 
(UKPDS), [11] STOP-NIDDM, [3] the Alpha-glucosi-
dase-inhibitor Blocks Cardiac Events in Patients with 
Myocardial Infarction and Impaired Glucose Tolerance 
(ABC) trial, [12] and the ACE trial [5] (Table 1).
The CV outcome definition used in all four trials was 
MACE-3: plus unstable angina and congestive heart 
failure for UKPDS and ACE; plus angina, coronary 
revascularization, congestive heart failure and periph-
eral vascular disease for STOP-NIDDM; plus unsta-
ble angina and coronary revascularization for ABC. 
UKPDS, ABC and ACE showed no difference between 
treatment groups with respect to their CV outcome, 
with HRs ranging from 0.98 to 1.24 for AGI compared 
with placebo). STOP-NIDDM, however, showed a 49% 
reduction (HR 0.51, 95% CI 0.28–0.95, p = 0.03) but 
with only 47 composite CV events in total, compared 
with 100 in UKPDS and 949 in ACE. Overall, our meta-
analysis showed no reduction in CV events for AGIs 
compared with placebo (HR 0.98, 95% CI 0.89–1.10, 
p = 0.85), with an  I2 value of 0% (p = 0.79) showing no 
heterogeneity between studies (Fig.  3), and the funnel 
plot (Additional file 1: Figure S2) indicating that publi-
cation bias is unlikely.
Fig. 1 Selection of eligible trials
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Discussion
This meta-analysis shows an overall statistically sig-
nificant 23% reduced risk of new-onset diabetes with 
AGIs in people with IGT (p < 0.0001). These results 
affirm the benefit of AGIs in reducing the risk of new-
onset diabetes, and with acarbose licensed in China and 
52 other countries for the treatment of IGT affords a 
pharmacological opportunity to help in the battle to con-
tain the worldwide diabetes epidemic of type 2 diabetes 
[13].
AGIs, however, showed no overall impact of on 
CV outcomes, suggesting that the 49% risk reduction 
reported for the STOP-NIDDM [3] was most likely a 
chance finding, particularly with so few events for this 
Fig. 2 Forest plot of incident diabetes results for each trial and overall effect
Fig. 3 Forest plot of incident cardiovascular outcome results for each trial and overall effect
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secondary outcome, although this was a primary CVD 
prevention population mostly not taking cardioprotective 
medications such as statins and renin-angiotensin system 
inhibitors. An earlier meta-analysis of randomised con-
trolled trials of alpha-glucosidase inhibitors suggested 
that they may prevent the progression if carotid intima 
thickness in patients with IGT or type 2 diabetes, [14] 
but our CV meta-analysis suggests this does not trans-
late into fewer CV events. Our analysis was driven by the 
neutral outcome results reported by ACE [5] and UKPDS 
[11], with 949 and 200 events respectively, suggests that 
AGIs neither increase nor decrease the risk of major 
adverse cardiovascular events in people with IGT or dia-
betes, although given the mean follow-up for this analy-
sis is 4.0 years the possibility that AGI use might reduce 
CV risk in the longer term cannot be excluded. Aggres-
sive treatment of other cardiovascular risk factors, such 
as hypertension and dyslipidemia, as well as the use of 
antiplatelet therapy and inhibitors of the renin angioten-
sin system have resulted in significant reductions in CVD 
events in populations with [15] or without diabetes [16]. 
However, the impact of glycaemic reduction on CV dis-
ease is modest, [17] possibly making it difficult to detect 
the effect of some glucose-lowering agents, especially 
when added to optimized CV risk therapy. Recent stud-
ies have demonstrated cardio protection with sodium-
glucose cotransporter-2 inhibitors and glucagon-like 
peptide-1 receptor agonists [18, 19] probably via non-
glycaemic mechanisms. AGIs, however, might reduce CV 
risk indirectly in the longer term by delaying the onset of 
type 2 diabetes in people with IGT [20]. Such an effect 
was seen in the Chinese Da Qing study where a 6-year 
lifestyle intervention program which delayed the onset of 
type 2 diabetes was shown to be associated with an 11.9% 
reduction in CV death and a 28.1% reduction in all-cause 
mortality after 23 years follow-up [21].
Strengths of these analyses include the use of data from 
all randomized controlled trials reporting outcomes that 
could be compared, with a minimum 1-year follow-up to 
enable collection and adjudication of the required end-
points (>1600 incident diabetes events and > 1200 CV 
events). Our meta-analysis has several limitations. We 
used study-level rather than patient-level data, which 
is considered the gold standard for meta-analysis and 
which restricts our ability to investigate further any sub-
groups of interest.
Only a small number of eligible trials could be identi-
fied, although it is noteworthy that for CV outcomes no 
other trials with published CV outcomes would have 
been excluded by our selection criteria. For incident 
diabetes, a further two small-scale trials were identi-
fied but not included. These were the Early Diabe-
tes Intervention programme (EDIP), which reported 
62 events of progression to type 2 diabetes defined as 
FPG ≥ 7.8  mmol/l in 196 subjects followed for 5  years, 
[22] and the Dutch acarbose intervention study in per-
sons with impaired glucose tolerance (DAISI) which 
reported 25 events of progression to diabetes in 118 
individuals followed for 3  years based on a single glu-
cose measurement [23]. Although these trials did not 
meet our inclusion criteria, we conducted a sensitiv-
ity analysis for incident diabetes which yielded a similar 
result (HR 0.74 [95% CI 0.67–0.82], p < 0.0001). In addi-
tion, the Cochrane collaboration recently published the 
results of trials reporting the incidence of type 2 diabe-
tes, and separately CV mortality, non-fatal MI and non-
fatal stroke in all populations without normal glucose 
levels (impaired fasting glucose, IGT or elevated  HbA1c) 
[24], which yielded similar results to our analysis show-
ing a type 2 diabetes incidence risk ratio of 0.73 (95% CI 
0.59–0.90), but the combined MACE-3 endpoint was not 
reported.
Conclusion
This meta-analysis demonstrates that the overall impact 
of AGIs on CV outcomes is neutral, it is clear that they 
cannot be indicated for CV secondary prevention. To 
date, although many countries have licensed AGIs for use 
in IGT, very few currently approve any medication for 
diabetes prevention. Given that this meta-analysis dem-
onstrates that allocation of people with IGT to an AGI 
can significantly reduce their risk of incident diabetes, 
AGIs should be considered as one approach to delaying 
or preventing new-onset diabetes in people with or with-
out pre-existing CV disease.
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